Dallas, Texas 04/09/2014 (FINANCIALSTRENDS) – Dyax Corp. (NASDAQ:DYAX) the biopharmaceutical service provider which has finally received positive news for its plasma inhibitor called KALBITOR.
Food and Drug Administration has indicated that the peptide-based inhibitor can now be used for treating a special medical condition called Hereditary Angioedema or HAE for patients aged 12 years and more.
Incidentally, this is the first, subcutaneous therapy to treat acute HAE attacks for patients less than 12 years.
Dyax Corp. (NASDAQ:DYAX) has reported that this drug is the only approved therapy which will not purify human plasma, when it is used to treat patient populations.
KALBITOR is the only product Dyax Corp markets.
Dyax Corp. (NASDAQ:DYAX) has been able to seek FDA approval for this late 2009 approved drug, then limited to use on patients above 16 years, because of the data it was able to establish for its twin Phase 3 trails – EDEMA 3 and EDEMA4, both of which were completed earlier. The results of this data along with the DX-88/19 study have led encouraging efficacy and sustainable use, allowing FDA to stamp approval.
Kalbitor, the unique plasma inhibitor in Dyax Corp. (NASDAQ:DYAX) single-product portfolio. The company has reported net sales this year to the tune of $40.5million in 2013.
This product is expecting net sales in the range of $44million to $49 million in 2014. It is expected that the product will see high sales this year. HAE, which is a genetic deficiency of the rarest kind is typically severe and will also cause swelling which is painful.
For this rare disease therapy provider, the immediate competition comes from products developed by Shire. The products are named Cinryze and Firazyr. As per latest country-wide statistics on the number of HEA affected, nearly 6,500 are noticeably HAE positive and need medical intervention.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.